Drugs Made In America Acquisition Corp. (DMAA)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2025-Dec-312025-Sep-302025-Jun-302025-Mar-312024-Dec-31
Fiscal PeriodQ4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024
Total Assets239,918,847$237,632,428$235,205,692$232,806,487$550,824$
Total Current Assets12,191$28,196$49,726$71,019$4,991$
Cash and Cash Equivalents
Receivables
Other Current Assets
Assets Held for Sale in Short Term
Total Noncurrent Assets239,906,656$237,604,232$235,155,966$232,735,468$545,833$
Goodwill
Other Intangible Assets
Physical Assets
Other Noncurrent Assets
Assets Held for Sale in Long Term
Total Liabilities7,276,172$7,356,611$7,201,441$7,247,369$795,669$
Total Current Liabilities376,172$456,611$301,441$347,369$795,669$
Accounts Payable
Short Term Debt
Short Term Capital Lease Obligations
Other Current Liabilities
Total Noncurrent Liabilities6,900,000$6,900,000$6,900,000$6,900,000$0$
Long Term Debt
Long Term Capital Lease Obligations
Other Noncurrent Liabilities
Total Equity(7,263,981$)(7,328,415$)(7,151,715$)(7,176,350$)(244,845$)(164,859$)(19,931$)
Equity to Minority
Equity to Common Shareholders(7,263,981$)(7,328,415$)(7,151,715$)(7,176,350$)(244,845$)(164,859$)(19,931$)
Additional Paid-In Capital34,014$
Retained Earnings(7,265,053$)(6,720,645$)(6,456,942$)(6,325,023$)(279,845$)
Treasury Stock
Capital Lease Obligations